Please login to the form below

Orencia

This page shows the latest Orencia news and features for those working in and with pharma, biotech and healthcare.

Opdivo drives growth at BMS, but US sales slow down

Overall, BMS reported fourth-quarter revenues up 22% to $5.2bn, with a solid showing from novel oral anticoagulant Eliquis (apixaban), which leaped 57% to $346m and rheumatoid arthritis therapy Orencia

Latest news

Opdivo drives gain in BMS sales, but business revamp coming

Away from cancer, rheumatoid arthritis treatment Orencia (abatacept) continued its buoyant run with an 18% increase to $572m, while novel oral anticoagulant Eliquis (apixaban) brought in $884m, a rise of 90%.
Shire gives up on Momenta-partnered Humira biosimilar

It also has a biosimilar collaboration with generics giant Mylan covering six biologics, headed by M834, a biosimilar version of Bristol-Myers Squibb's rheumatoid arthritis drug Orencia (abatacept).
Mylan buys into six biosimilars, including Orencia candidate

Mylan buys into six biosimilars, including Orencia candidate. Deal with Momenta bolsters biosimilars pipeline for new products. ... The agreement gives Mylan the rights to six biosimilars in Momenta's pipeline, including a version of Bristol-Myers
NICE backs four treatments for juvenile idiopathic arthritis

NICE backs four treatments for juvenile idiopathic arthritis. Includes BMS' Orencia and AbbVie's Humira. ... The institute backed Bristol-Myers Squibb's Orencia (abatacept), AbbVie's Humira (adalimumab), Pfizer's Enbrel (etanercept) and Roche's RoActemra
NICE backs biosimilars in rheumatoid arthritis guidance

Orencia (abatacept) and MSD/J&J's Remicade (infliximab).

More from news
Approximately 10 fully matching, plus 33 partially matching documents found.

Latest Intelligence

Deal Watch January 2016

255. Mylan/ Momenta. Co-development, co-commercialisation . Exclusive global collaboration with Momenta for 6 biosimilars including a biosimilar version of Orencia (abatacept).
Biosimilars - the same, but different?

Orencia and Actemra for rheumatoid arthritis.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

BMS’ Brian Daniels to retire

Dr Daniels has been with BMS since 2000 as VP of the immunology, pulmonary, and dermatology therapeutic area where he worked on such compounds as rheumatoid arthritis drug Orencia (abatacept).

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Brand leaders in RA will lose market share, predict rheumatologists

market leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Medical Writer - Creative and Scientific Projects: DOE

Associate Scientific Director: Salary TBC

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Healthcare PR Senior Account Manager: Salary TBC

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Graduate Scientific Editor: DOE

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Healthcare PR Director: £100, 000 – £120, 000 benefits

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Account Director or Senior Account Director: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Account Director, Healthcare Advertising Agency: Salary TBC

Senior Medical Writer: Salary is DOE

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Account Manager: Negotiable

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Systematic Review Lead- London: Negotiable

Senior Training Manager - Surrey: Competitive Salary &Bonus

Subscribe to our email news alerts

PMHub

Add my company

Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

The gene therapy revolution: Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...